financetom
Business
financetom
/
Business
/
Estee Lauder names Stephane de La Faverie as CEO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Estee Lauder names Stephane de La Faverie as CEO
Nov 3, 2024 2:48 PM

Oct 30 (Reuters) - Cosmetics giant Estee Lauder ( EL )

on Wednesday named Stephane de La Faverie as its new president

and CEO, effective Jan. 1, 2025.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Rumble Stock?
What's Going On With Rumble Stock?
Mar 26, 2024
Rumble Inc. ( RUM ) shares are trading higher Tuesday, possibly in sympathy with Trump Media & Technology Group Corp. after the company debuted on the Nasdaq Tuesday.  What To Know: Trump Media & Technology Group debuted on the Nasdaq Tuesday. Rumble CEO Chris Pavlovski congratulated the company and its CEO on the social media platform, X.  A big congrats...
Marathon Oil Insider Sold Shares Worth $1,418,051, According to a Recent SEC Filing
Marathon Oil Insider Sold Shares Worth $1,418,051, According to a Recent SEC Filing
Mar 26, 2024
04:52 PM EDT, 03/26/2024 (MT Newswires) -- Michael A Henderson, Executive Vice President, Operations, on March 25, 2024, sold 51,389 shares in Marathon Oil ( MRO ) for $1,418,051. Following the Form 4 filing with the SEC, Henderson has control over a total of 114,828 shares of the company, with 114,828 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/101778/000010177824000066/xslF345X03/wk-form4_1711486143.xml Price: 27.4, Change:...
Looking At Applied Mat's Recent Unusual Options Activity
Looking At Applied Mat's Recent Unusual Options Activity
Mar 26, 2024
Whales with a lot of money to spend have taken a noticeably bullish stance on Applied Mat. Looking at options history for Applied Mat we detected 21 trades. If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 47% with bearish. From the overall spotted trades,...
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
Mar 26, 2024
04:49 PM EDT, 03/26/2024 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer. The company said the filing was assigned a prescription drug user fee act target action date...
Copyright 2023-2026 - www.financetom.com All Rights Reserved